Health and Healthcare
Merck (MRK): The Beatings Will Continue Until Morale Improves
Published:
Big Pharma continues to throw ballast out of the balloon in the hopes of staying aloft. The latest victim of declining fortunes in the industry is Merck (MRK), which seems to have had every drug which it submitted to the FDA this year turned down.
Merck’s cholesterol medicine Cordaptive got the thumbs down last week. Researchers are also questioning the value of its Vytorin product, another cholesterol treatment which does not seem to work.
According to The Wall Street Journal, Merck will cut 1,200 sales jobs.
There are more to come. The problems Merck has replacing drugs which are coming off-patent are getting deeper and deeper.
Douglas A. McIntyre
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
